Organon & Co. (OGN) CEO Kevin Ali on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/17/22
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021Business Wire • 02/17/22
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People's Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in VietnamBusiness Wire • 02/16/22
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022Business Wire • 02/01/22
Healthy Dividends: Organon's Dividend Bolsters The Long-Term Investment In A Fresh TickerSeeking Alpha • 01/22/22
Organon & Co. (OGN) CEO Kevin Ali on JPMorgan 40th Annual Healthcare Conference (Transcript)Seeking Alpha • 01/11/22
FDA Accepts Samsung Bioepis' and Organon's sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar CandidateBusiness Wire • 01/05/22
Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual ConferenceBusiness Wire • 12/20/21
Organon's acquisition of Karolinska Development's portfolio company Forendo Pharma has been successfully completedGlobeNewsWire • 12/13/21
Karolinska Development AB (publ) proposes a rights issue of approximately SEK 491 million, and publishes a proposal for a new Board memberGlobeNewsWire • 12/10/21
Organon & Co. (OGN) CEO Kevin Ali at 4th Annual Evercore ISI HealthCONx Conference (Transcript)Seeking Alpha • 12/01/21
Accenture and Organon Team Up to Drive Digital Transformation for Better Patient and Employee ExperiencesBusiness Wire • 11/17/21
Organon: Post Earnings Dip Is A Buy Opportunity Based On Jaw-Dropping FundamentalsSeeking Alpha • 11/13/21
Organon & Co. (OGN) CEO Kevin Ali on Q3 2021 Earnings Conference Call - Earnings Call TranscriptSeeking Alpha • 11/11/21